English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Takeda’s DPP-4 Treatment for Type 2 Diabetes Approved in China

Jul. 31, 2013

On July 31, 2013 Takeda Pharma announced that the CFDA has issued an Import Drug License (IDL) for NESINA (alogliptin), a drug for the treatment of type 2 diabetes. NESINA is an orally-administered dipeptidyl peptidase-4 inhibitor (DPP-4i) designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). As a result, an increased amount of active incretins enables the pancreas to secrete insulin in a glucose-dependent manner, thereby assisting in the management of blood glucose levels. China has the largest number of people with diabetes compared to any other country, with approximately 92.3 million adults suffering from the disease, 58.5% of which are undiagnosed. By 2030, an additional 37.4 million Chinese adults are expected to develop type 2 diabetes.